BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...to Selective Estrogen Receptor Degrader (SERD) company Seragon Pharmaceuticals Inc....
BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

...ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) and helped found cancer company Aragon Pharmaceuticals Inc. and its spinout Seragon Pharmaceuticals Inc....
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

...Founded by Charles Sawyers and Richard Heyman, the duo behind Aragon Pharmaceuticals and its spinout Seragon...
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

...front and up to $350 million in milestones; and Roche (SIX:ROG; OTCQX:RHHBY) bought Aragon’s spinout, Seragon Pharmaceuticals Inc....
BioCentury | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

...more than $175 million, was founded by the duo behind Aragon Pharmaceuticals and its spinout Seragon...
...Heyman is ORIC's chairman. Together, they previously founded drug-resistant cancer companies Aragon Pharmaceuticals Inc. and Seragon Pharmaceuticals Inc....
...NT5E) - Ecto-5’-nucleotidase; GCCR - Glucocorticoid receptor Elizabeth S. Eaton, Staff Writer ORIC-101 Aragon Pharmaceuticals Inc. Ignyta Inc. ORIC Pharmaceuticals Inc. Seragon Pharmaceuticals Inc....
BioCentury | Jul 13, 2018
Strategy

Roche’s partnering priority

...flow. Only one of those was an acquisition of a company, the 2014 deal for Seragon Pharmaceuticals Inc....
BioCentury | Feb 2, 2018
Financial News

Partner Therapeutics raises $60M, in-licenses Leukine

...Mulroy was president and CEO at Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), and Roychowdhury was CMO of Seragon Pharmaceuticals Inc....
BioCentury | Feb 2, 2018
Company News

Partner Therapeutics raises $60M, in-licenses Leukine

...Mulroy was president and CEO at Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), and Roychowdhury was CMO of Seragon Pharmaceuticals Inc....
...date. Partner Therapeutics Inc., Boston, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Cancer Jennie Walters Partner Therapeutics Inc.SanofiRocheSeragonMerrimack...
BioCentury | Feb 1, 2018
Company News

Roche halts SERD from Seragon, reports earnings

...its Genentech Inc. unit acquired Seragon Pharmaceuticals Inc. in 2014. This is the second SERD candidate from Seragon...
...see BioCentury Extra, March 29, 2017 & BioCentury Extra, Jan. 12, 2018) . Elizabeth S. Eaton ocrelizumab Ocrevus RG6046 RG6047 Genentech Inc. Seragon Pharmaceuticals Inc. Roche...
BioCentury | Jan 26, 2018
Company News

Management tracks: Partner Therapeutics, Merck

...was co-founder, CEO and president of Merrimack Pharmaceuticals Inc. (NASDAQ:MACK). CMO Roychowdhury was CMO of Seragon Pharmaceuticals Inc....
Items per page:
1 - 10 of 37
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...to Selective Estrogen Receptor Degrader (SERD) company Seragon Pharmaceuticals Inc....
BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

...ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) and helped found cancer company Aragon Pharmaceuticals Inc. and its spinout Seragon Pharmaceuticals Inc....
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

...Founded by Charles Sawyers and Richard Heyman, the duo behind Aragon Pharmaceuticals and its spinout Seragon...
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

...front and up to $350 million in milestones; and Roche (SIX:ROG; OTCQX:RHHBY) bought Aragon’s spinout, Seragon Pharmaceuticals Inc....
BioCentury | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

...more than $175 million, was founded by the duo behind Aragon Pharmaceuticals and its spinout Seragon...
...Heyman is ORIC's chairman. Together, they previously founded drug-resistant cancer companies Aragon Pharmaceuticals Inc. and Seragon Pharmaceuticals Inc....
...NT5E) - Ecto-5’-nucleotidase; GCCR - Glucocorticoid receptor Elizabeth S. Eaton, Staff Writer ORIC-101 Aragon Pharmaceuticals Inc. Ignyta Inc. ORIC Pharmaceuticals Inc. Seragon Pharmaceuticals Inc....
BioCentury | Jul 13, 2018
Strategy

Roche’s partnering priority

...flow. Only one of those was an acquisition of a company, the 2014 deal for Seragon Pharmaceuticals Inc....
BioCentury | Feb 2, 2018
Financial News

Partner Therapeutics raises $60M, in-licenses Leukine

...Mulroy was president and CEO at Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), and Roychowdhury was CMO of Seragon Pharmaceuticals Inc....
BioCentury | Feb 2, 2018
Company News

Partner Therapeutics raises $60M, in-licenses Leukine

...Mulroy was president and CEO at Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), and Roychowdhury was CMO of Seragon Pharmaceuticals Inc....
...date. Partner Therapeutics Inc., Boston, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Cancer Jennie Walters Partner Therapeutics Inc.SanofiRocheSeragonMerrimack...
BioCentury | Feb 1, 2018
Company News

Roche halts SERD from Seragon, reports earnings

...its Genentech Inc. unit acquired Seragon Pharmaceuticals Inc. in 2014. This is the second SERD candidate from Seragon...
...see BioCentury Extra, March 29, 2017 & BioCentury Extra, Jan. 12, 2018) . Elizabeth S. Eaton ocrelizumab Ocrevus RG6046 RG6047 Genentech Inc. Seragon Pharmaceuticals Inc. Roche...
BioCentury | Jan 26, 2018
Company News

Management tracks: Partner Therapeutics, Merck

...was co-founder, CEO and president of Merrimack Pharmaceuticals Inc. (NASDAQ:MACK). CMO Roychowdhury was CMO of Seragon Pharmaceuticals Inc....
Items per page:
1 - 10 of 37